CN1314803C - 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 - Google Patents

含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 Download PDF

Info

Publication number
CN1314803C
CN1314803C CNB028125703A CN02812570A CN1314803C CN 1314803 C CN1314803 C CN 1314803C CN B028125703 A CNB028125703 A CN B028125703A CN 02812570 A CN02812570 A CN 02812570A CN 1314803 C CN1314803 C CN 1314803C
Authority
CN
China
Prior art keywords
antibody
glypican
cells
antibodies
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028125703A
Other languages
English (en)
Chinese (zh)
Other versions
CN1688692A (zh
Inventor
中村彻雄
土屋政幸
油谷浩幸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN1688692A publication Critical patent/CN1688692A/zh
Application granted granted Critical
Publication of CN1314803C publication Critical patent/CN1314803C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNB028125703A 2001-06-22 2002-06-21 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂 Expired - Lifetime CN1314803C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001189443 2001-06-22
JP189443/2001 2001-06-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2007100960379A Division CN101240022B (zh) 2001-06-22 2002-06-21 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂

Publications (2)

Publication Number Publication Date
CN1688692A CN1688692A (zh) 2005-10-26
CN1314803C true CN1314803C (zh) 2007-05-09

Family

ID=19028362

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028125703A Expired - Lifetime CN1314803C (zh) 2001-06-22 2002-06-21 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂
CN2007100960379A Expired - Lifetime CN101240022B (zh) 2001-06-22 2002-06-21 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007100960379A Expired - Lifetime CN101240022B (zh) 2001-06-22 2002-06-21 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂

Country Status (14)

Country Link
US (3) US20040236080A1 (https=)
EP (3) EP2208784B1 (https=)
JP (7) JP4281869B2 (https=)
KR (3) KR100953520B1 (https=)
CN (2) CN1314803C (https=)
AT (2) ATE483801T1 (https=)
AU (2) AU2002315857B2 (https=)
CA (1) CA2451493C (https=)
CY (1) CY1113854T1 (https=)
DE (2) DE60228721D1 (https=)
DK (2) DK1411118T3 (https=)
ES (3) ES2312586T3 (https=)
PT (2) PT2208784E (https=)
WO (1) WO2003000883A1 (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
KR100953520B1 (ko) 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
MXPA04011132A (es) 2002-05-23 2005-08-15 Sunnybrook & Womens College Diagnostico de carcinoma hepatocelular.
WO2005023301A1 (ja) * 2003-09-04 2005-03-17 Chugai Seiyaku Kabushiki Kaisha 胆管癌治療剤および検出薬
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
JP4733042B2 (ja) 2004-08-24 2011-07-27 中外製薬株式会社 抗グリピカン３抗体を用いたアジュバント療法
AU2005297772B2 (en) * 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP1901573A1 (en) 2005-08-03 2008-03-19 Matsushita Electric Industrial Co., Ltd. Base station apparatus, communication terminal apparatus, and multicarrier communication method
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ME02345B (me) * 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
KR101680906B1 (ko) 2007-09-26 2016-11-30 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
US8497355B2 (en) 2007-09-28 2013-07-30 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
TW201634479A (zh) 2007-12-05 2016-10-01 中外製藥股份有限公司 抗ｎｒ１０抗體及其應用
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
US20120190049A1 (en) * 2010-12-10 2012-07-26 University Of Washington Through Its Center For Commercialization Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
EP2752200B1 (en) 2011-09-30 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule inducing immune response to target antigen
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6271251B2 (ja) 2011-10-05 2018-01-31 中外製薬株式会社 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
EP3738980A1 (en) 2012-02-24 2020-11-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
SG11201407972RA (en) * 2012-06-01 2015-01-29 Us Health High-affinity monoclonal antibodies to glypican-3 and use thereof
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
DK3078744T3 (da) 2013-12-04 2020-09-28 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyler, antigen-bindingsaktiviteten af hvilke varierer i henhold til koncentrationen af forbindelser, og biblioteker af molekylerne
JP6827319B2 (ja) 2014-05-08 2021-02-10 中外製薬株式会社 Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
US9926377B2 (en) * 2014-05-22 2018-03-27 Genentech, Inc. Anti-GPC3 antibodies and immunoconjugates
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN104829704B (zh) * 2014-12-15 2016-08-17 河北省科学院生物研究所 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
SG11201705808XA (en) * 2015-01-16 2017-08-30 Minomic Int Ltd Glypican epitopes and uses thereof
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
ES2883240T3 (es) * 2015-08-03 2021-12-07 Cafa Therapeutics Ltd Anticuerpo contra glipicano-3 y aplicación del mismo
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
RS65666B1 (sr) * 2015-11-09 2024-07-31 Childrens Hospital Philadelphia Glipikan 2 kao tumor marker i terapijski cilj
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US11767362B1 (en) * 2016-03-15 2023-09-26 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018038046A1 (ja) 2016-08-22 2018-03-01 中外製薬株式会社 ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
AR114112A1 (es) 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
US20210253672A1 (en) 2018-05-30 2021-08-19 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule containing single domain antibody
CA3102641A1 (en) 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
SG11202103234RA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS
SG11202104136YA (en) 2018-10-23 2021-05-28 Dragonfly Therapeutics Inc Heterodimeric fc-fused proteins
EP3943108A4 (en) 2019-03-19 2023-01-04 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH ANTIGEN-BINDING DOMAIN WITH VARIABLE BINDING ACTIVITY TO ANTIGEN DEPENDING ON MTA AND LIBRARY TO OBTAIN THE ANTIGEN-BINDING DOMAIN
CN114127277A (zh) 2019-06-05 2022-03-01 中外制药株式会社 蛋白酶底物和包含蛋白酶切割序列的多肽
WO2020246563A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 抗体切断部位結合分子
CN114391021B (zh) 2019-06-21 2026-01-16 凯德药业股份有限公司 TGF-β受体和使用方法
MX2022013112A (es) 2020-04-22 2023-01-16 Dragonfly Therapeutics Inc Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
WO2022261061A1 (en) 2021-06-08 2022-12-15 Kite Pharma, Inc. Gpc3 binding molecules
CN118488970A (zh) * 2021-10-15 2024-08-13 乐普创一生物科技（上海）有限公司 抗磷脂酰肌醇蛋白聚糖3抗体
KR20260020412A (ko) 2023-06-16 2026-02-11 살루브리스 (청두) 바이오테크 코., 리미티드 항-gpc3 항체 또는 항원 결합 단편 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH04228089A (ja) 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
US6214973B1 (en) * 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
JP3587664B2 (ja) 1996-10-04 2004-11-10 中外製薬株式会社 再構成ヒト抗ｈｍ１．２４抗体
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP4228089B2 (ja) 1997-03-11 2009-02-25 株式会社ニコン 過電流検知機構およびそれを用いた電子閃光装置
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
RU2221809C2 (ru) 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
JP3445153B2 (ja) 1998-06-04 2003-09-08 富士通株式会社 電話番号一時的使用装置及び方法
AU784460B2 (en) 1999-08-23 2006-04-06 Chugai Seiyaku Kabushiki Kaisha HM1.24 antigen expression potentiators
KR100953520B1 (ko) * 2001-06-22 2010-04-21 츄가이 세이야꾸 가부시키가이샤 항글리피칸 3항체를 포함하는 항암제

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLONING AND CHARACTERIZATION OF HUMAN CDNAS ENCODING APROTEIN WITH HIGH HOMOLOGY TO TAT INTESTINAL DEVELOPEMNTPROTEIN OCI-5 LAGE H ET AL,GENE VOL,Vol.188 No.02 1997 *
CLONING AND EXPRESSION OF A DEVELOPMENTALLY REGULATEDTRANSERIPT MXR7 IN HEPATOCELLULAR CARCINOMA BIOLOGICALSIGNIFICANCE AND TEMPOROSPATIAL HSU H C ET AL,CANCER RES,Vol.57 No.22 1997 *
Developmental regulation of the soluble formof insulin-like growth factor-II/mannose 6-phosphate receptorin human serum and amniotic fluid. XU Y ET AL,JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM,Vol.83 No.2 1998 *
Glypican-3 is a potential tumor marker forhepatocellular carcinoma KLEEFF J H ET AL:,GASTROENTEROLOGY,Vol.118 No.1 2000 *
Mutations in GPC3, a glypican gene,cause the Simpson-Golabi-Behmel overgrowth syndrome PILIA G. ET AL,NAT. GENET.,Vol.12 No.3 1996 *
OCI-5/GPC3,AGLYPICAN ENCODED BY A GENE THAT IS MUTATEDIN THE SIMPSON-GOLABI-BEHMEL OVERGROWTH SYNDOME INDUCESAPOPTOSIS IN A CELL LINE SPECIFIC MANNER GONZALEZ A D ET AL,J CELL BIOL,Vol.141 No.6 1998 *

Also Published As

Publication number Publication date
EP1411118A1 (en) 2004-04-21
JP4347402B2 (ja) 2009-10-21
KR20080077295A (ko) 2008-08-21
EP1780273A1 (en) 2007-05-02
US20070172488A1 (en) 2007-07-26
JP5596935B2 (ja) 2014-09-24
EP1411118B1 (en) 2008-09-03
ES2353335T3 (es) 2011-03-01
JP4281869B2 (ja) 2009-06-17
DE60228721D1 (en) 2008-10-16
JP2007238632A (ja) 2007-09-20
CN1688692A (zh) 2005-10-26
KR20040030699A (ko) 2004-04-09
JP2007051159A (ja) 2007-03-01
ES2312586T3 (es) 2009-03-01
US20110002922A1 (en) 2011-01-06
KR100953520B1 (ko) 2010-04-21
CY1113854T1 (el) 2016-07-27
CN101240022A (zh) 2008-08-13
AU2007201255A1 (en) 2007-04-19
JP2009024020A (ja) 2009-02-05
DK2208784T3 (da) 2013-03-18
CA2451493A1 (en) 2003-01-03
JPWO2003000883A1 (ja) 2004-10-07
HK1120522A1 (en) 2009-04-03
US8263077B2 (en) 2012-09-11
EP2208784A1 (en) 2010-07-21
CA2451493C (en) 2016-08-23
ES2399028T3 (es) 2013-03-25
AU2002315857B2 (en) 2007-07-26
US20040236080A1 (en) 2004-11-25
US7744880B2 (en) 2010-06-29
HK1079547A1 (en) 2006-04-07
ATE483801T1 (de) 2010-10-15
KR20090107091A (ko) 2009-10-12
EP1780273B1 (en) 2010-10-06
EP2208784B1 (en) 2013-01-02
KR100877176B1 (ko) 2009-01-07
WO2003000883A1 (fr) 2003-01-03
PT2208784E (pt) 2013-04-03
DK1411118T3 (da) 2008-11-17
DE60237929D1 (de) 2010-11-18
JP2009161565A (ja) 2009-07-23
PT1411118E (pt) 2008-12-09
CN101240022B (zh) 2012-07-18
JP2008120828A (ja) 2008-05-29
EP1411118A4 (en) 2005-01-26
ATE407204T1 (de) 2008-09-15
JP2005225892A (ja) 2005-08-25
AU2007201255B2 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
CN1314803C (zh) 含有抗磷脂酰肌醇蛋白聚糖3抗体的细胞生长抑制剂
JP5554993B2 (ja) Ａｎｅｘｅｌｅｋｔｏに結合するモノクローナル抗体、およびその利用
US8546546B2 (en) Anti-Muc 17 antibody
JP4733042B2 (ja) 抗グリピカン３抗体を用いたアジュバント療法
HK1079547B (en) Cell growth inhibitors containing anti-glypican 3 antibody
US20100111851A1 (en) Diagnosis and treatment of cancer by using anti-prg-3 antibody
HK1120522B (en) Cell growth inhibitors containing anti-glypican 3 antibody
HK1060368A (en) Cell proliferation inhibitors containing anti-glypican 3 antibody

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079547

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060915

Address after: Tokyo, Japan

Applicant after: Chugai Pharmaceutical Co.,Ltd.

Co-applicant after: Perseus protein Group Co.

Address before: Tokyo, Japan

Applicant before: Chugai Pharmaceutical Co.,Ltd.

Co-applicant before: Hiroyuki Aburatani

ASS Succession or assignment of patent right

Owner name: CHOONGWAE PHARMACUTICAL CORP.

Free format text: FORMER OWNER: CHOONGWAE PHARMACUTICAL CORP.; APPLICANT

Effective date: 20061124

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20061124

Address after: Tokyo, Japan

Applicant after: Chugai Pharmaceutical Co.,Ltd.

Address before: Tokyo, Japan

Applicant before: Chugai Pharmaceutical Co.,Ltd.

Co-applicant before: Perseus protein Group Co.

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20070509

CX01 Expiry of patent term